Yu Mingjie, Wang Ping
Nuclear Medicine Department, The People's Hospital of Bozhou, Bozhou, 236800, China.
Clinical Laboratory, Bozhou Hospital of Traditional Chinese Medicine, Northwest of the intersection of Weiwu Avenue and North First Ring Road, Qiaocheng District, Bozhou, 236800, China.
Discov Oncol. 2024 Sep 27;15(1):485. doi: 10.1007/s12672-024-01323-3.
Small Cell Lung Cancer (SCLC) presents a significant clinical challenge due to its aggressive nature and the need for effective biomarkers for treatment monitoring. This study aimed to compare ProGRP and CEA as serological markers in the monitoring of SCLC treatment.
We retrospectively analyzed data from 80 SCLC patients and 80 matched controls. ProGRP and CEA levels were measured, and their associations with clinical parameters, including tumor stage and treatment response, were assessed using Spearman's rank correlation coefficient. Multivariate logistic regression models were employed to identify independent predictors of treatment response and disease progression.
ProGRP and CEA levels were considerably higher in cases than controls, with median ProGRP levels at 198.5 pg/mL versus 48.7 pg/mL and median CEA levels at 5.2 ng/mL versus 2.9 ng/mL (both p < 0.001). ProGRP levels correlated positively with tumor stage (ρ = 0.58, p < 0.001) and negatively with treatment response (ρ = - 0.45, p = 0.001). CEA levels also showed positive correlation with tumor stage (ρ = 0.48, p = 0.002) and negative correlation with treatment response (ρ = - 0.35, p = 0.005). Multivariate analysis revealed that ProGRP was an independent predictor for treatment response (OR 1.25 per 100 pg/mL increase, p = 0.001) and disease progression (OR 1.25 per 50 pg/mL increase, p = 0.012), while CEA was a marginal predictor for treatment response (OR 0.95 per 1 ng/mL increase, p = 0.045).
Both ProGRP and CEA are significant serological markers in SCLC patients, with ProGRP showing a stronger correlation with tumor stage and treatment response. ProGRP may serve as a superior independent predictor of treatment response and disease progression compared to CEA. These findings support the incorporation of ProGRP in SCLC treatment monitoring protocols.
小细胞肺癌（SCLC）因其侵袭性以及需要有效的生物标志物来监测治疗，带来了重大的临床挑战。本研究旨在比较ProGRP和CEA作为SCLC治疗监测中的血清学标志物。
我们回顾性分析了80例SCLC患者和80例匹配对照的数据。测量了ProGRP和CEA水平，并使用Spearman等级相关系数评估它们与包括肿瘤分期和治疗反应在内的临床参数的关联。采用多变量逻辑回归模型来确定治疗反应和疾病进展的独立预测因素。
病例组的ProGRP和CEA水平显著高于对照组，ProGRP的中位数水平为198.5 pg/mL，而对照组为48.7 pg/mL；CEA的中位数水平为5.2 ng/mL，而对照组为2.9 ng/mL（两者p < 0.001）。ProGRP水平与肿瘤分期呈正相关（ρ = 0.58，p < 0.001），与治疗反应呈负相关（ρ = -0.45，p = 0.001）。CEA水平也与肿瘤分期呈正相关（ρ = 0.48，p = 0.002），与治疗反应呈负相关（ρ = -0.35，p = 0.005）。多变量分析显示，ProGRP是治疗反应（每增加100 pg/mL，OR为1.25，p = 0.001）和疾病进展（每增加50 pg/mL，OR为1.25，p = 0.012）的独立预测因素，而CEA是治疗反应的边缘预测因素（每增加1 ng/mL，OR为0.95，p = 0.045）。
ProGRP和CEA都是SCLC患者重要的血清学标志物，ProGRP与肿瘤分期和治疗反应的相关性更强。与CEA相比，ProGRP可能是治疗反应和疾病进展的更优独立预测因素。这些发现支持将ProGRP纳入SCLC治疗监测方案。
